1PK0

Crystal Structure of the EF3-CaM complexed with PMEApp

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 0.302 
  • R-Value Work: 0.264 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history. 


Literature

Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Shen, Y., Zhukovskaya, N.L., Zimmer, M.I., Soelaiman, S., Bergson, P., Wang, C.R., Gibbs, C.S., Tang, W.J.

(2004) Proc Natl Acad Sci U S A 101: 3242-3247

  • DOI: 10.1073/pnas.0306552101
  • Primary Citation of Related Structures:  
    1PK0

  • PubMed Abstract: 

    • Edema factor (EF), a key virulence factor in anthrax pathogenesis, has calmodulin (CaM)-activated adenylyl cyclase activity. We have found that adefovir dipivoxil, a drug approved to treat chronic infection of hepatitis B virus, effectively inhibits EF-i ...

    Edema factor (EF), a key virulence factor in anthrax pathogenesis, has calmodulin (CaM)-activated adenylyl cyclase activity. We have found that adefovir dipivoxil, a drug approved to treat chronic infection of hepatitis B virus, effectively inhibits EF-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages. Adefovir diphosphate (PMEApp), the active cellular metabolite of adefovir dipivoxil, inhibits the adenylyl cyclase activity of EF in vitro with high affinity (K(i) = 27 nM). A crystal structure of EF-CaM-PMEApp reveals that the catalytic site of EF forms better van der Waals contacts and more hydrogen bonds with PMEApp than with its endogenous substrate, ATP, providing an explanation for the approximately 10,000-fold higher affinity EF-CaM has for PMEApp versus ATP. Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin. It can be used to address the role of EF in anthrax pathogenesis.

    Related Citations: 
    • Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins
      Shen, Y.-Q., Lee, Y.-S., Soelaiman, S., Bergson, P., Lu, D., Chen, A., Beckingham, K., Grabarek, Z., Mrksich, M., Tang, W.-J.
      (2002) EMBO J 21: 6721
    Organizational Affiliation: 

    Ben-May Institute for Cancer Research, University of Chicago, 924 East 57th Street, Chicago, IL 60637, USA.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Calmodulin-sensitive adenylate cyclase A, B, C507Bacillus anthracisMutation(s): 0 
Gene Names: CYA OR PXO1-122, cya, pXO1-122, BXA0141, GBAA_pXO1_0142
EC: 4.6.1.1
Find proteins for P40136 (Bacillus anthracis)
Explore P40136 
Go to UniProtKB:  P40136
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Calmodulin D, E, F147Homo sapiensMutation(s): 0 
Gene Names: (CALM1 OR CAM1 OR CALM OR CAM), CALM1, CALM, CAM, CAM1
Find proteins for P0DP23 (Homo sapiens)
Explore P0DP23 
Go to UniProtKB:  P0DP23
NIH Common Fund Data Resources
PHAROS:  P0DP23
GTEx:  ENSG00000198668
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.30 Å
  • R-Value Free: 0.302 
  • R-Value Work: 0.264 
  • Space Group: I 2 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 116.263α = 90
b = 165.759β = 90
c = 342.409γ = 90
Software Package:
Software NamePurpose
CNSrefinement
HKL-2000data reduction
SCALEPACKdata scaling
CNSphasing

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2003-06-04 
  • Released Date: 2004-02-10 
    • Deposition Author(s): Shen, Y., Tang, W.J.

Revision History 

  • Version 1.0: 2004-02-10
    Type: Initial release
  • Version 1.1: 2008-04-29
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Derived calculations, Version format compliance
  • Version 1.3: 2019-11-20
    Changes: Advisory, Derived calculations